Vasogen(加拿大)

Vasogen

加拿大VasogenIncwww.vasogen.comVasogenInc.(多倫多，Toronto)是以心血管疾病或神經(jīng)疾病所引發(fā)的慢性發(fā)炎作為治療標(biāo)靶，來(lái)進(jìn)行新藥物科技研發(fā)的公司，宣布ChristopherJ.Waddick被擢升為營(yíng)運(yùn)長(zhǎng)，PaulJ.VanDamme擔(dān)任財(cái)務(wù)部門(mén)副總裁及財(cái)務(wù)長(zhǎng)，JacquelineH.R.LeSaux擔(dān)任公司及法律業(yè)務(wù)部門(mén)副總裁Weareabiotechno logycompanythatisfocusedontheresearchandcommercialdevelopmentoftherapiesdesignedtotargetthedestructiveinflammatoryprocessesassociatedwiththedevelopmentandprogressionofcardiovascularandneuro-inflammatorydisorders.Ourmostadvancedproduct,theCelacade™System,isdesignedtoactivatetheimmuneresponsetoapoptosis–animportantphysiologicalprocessthatregulatesinflammation.Wearealsodevelopinganewclassofdrugsforthetreatmentofcertainneuro-inflammatorydisorders.Ourtwoinitialproductcandidates,VP015andVP025,arebiologicalligandsdesignedtoexploitspecificphysiologicalanti-inflammatoryresponsesoftheimmunesystem.Theeffectsofthesedrugshavebeenshowntocrosstheblood-brai